TOKYO KEIKI INC. (TYO:7721)

Ligand Pharmaceuticals Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	6,470	7,597	7,836	8,710	12,244	11,620
Cash & Short-Term Investments	6,470	7,597	7,836	8,710	12,244	11,620
Cash Growth	-31.73%	-3.05%	-10.03%	-28.86%	5.37%	50.73%
Accounts Receivable	14,540	23,232	19,292	17,380	15,328	16,380
Other Receivables	3,066	39	197	269	245	32
Receivables	17,606	23,271	19,489	17,649	15,573	16,412
Inventory	27,314	23,970	22,905	18,153	14,979	12,673
Other Current Assets	1,700	1,352	633	302	306	245
Total Current Assets	53,090	56,190	50,863	44,814	43,102	40,950
Property, Plant & Equipment	9,712	9,709	7,025	5,458	6,617	6,970
Long-Term Investments	-	10,246	8,905	5,655	6,049	5,312
Other Intangible Assets	256	223	185	137	94	33
Long-Term Deferred Tax Assets	-	130	-	560	157	281
Other Long-Term Assets	10,622	-1	-	-	-1	-
Total Assets	73,680	76,497	66,978	56,624	56,018	53,546
Accounts Payable	6,206	5,951	7,022	6,824	6,565	5,093
Accrued Expenses	741	1,462	1,256	1,145	1,159	1,097
Short-Term Debt	10,639	10,417	8,954	9,951	8,102	8,516
Current Income Taxes Payable	-	2,014	1,048	929	857	611
Other Current Liabilities	5,335	4,216	3,501	2,536	2,348	2,405
Total Current Liabilities	22,921	24,060	21,781	21,385	19,031	17,722
Long-Term Debt	8,245	9,062	5,808	-	2,136	2,424
Long-Term Deferred Tax Liabilities	-	562	360	-	-	-
Other Long-Term Liabilities	1,685	1,103	1,010	1,149	870	872
Total Liabilities	33,514	35,490	29,609	23,173	22,670	21,607
Common Stock	7,218	7,218	7,218	7,218	7,218	7,218
Additional Paid-In Capital	37	32	21	17	14	14
Retained Earnings	28,828	29,580	26,316	24,532	24,152	23,076
Treasury Stock	-649	-649	-653	-663	-675	-688
Comprehensive Income & Other	4,194	4,237	3,947	1,822	2,179	1,834
Total Common Equity	39,628	40,418	36,849	32,926	32,888	31,454
Minority Interest	538	589	520	525	460	485
Shareholders' Equity	40,166	41,007	37,369	33,451	33,348	31,939
Total Liabilities & Equity	73,680	76,497	66,978	56,624	56,018	53,546
Total Debt	18,884	19,479	14,762	9,951	10,238	10,940
Net Cash (Debt)	-12,414	-11,882	-6,926	-1,241	2,006	680
Net Cash Growth	-	-	-	-	195.00%	-
Net Cash Per Share	-755.60	-723.28	-421.75	-75.62	122.32	41.51
Filing Date Shares Outstanding	16.43	16.43	16.42	16.41	16.4	16.39
Total Common Shares Outstanding	16.43	16.43	16.42	16.41	16.4	16.39
Working Capital	30,169	32,130	29,082	23,429	24,071	23,228
Book Value Per Share	2412.04	2460.12	2243.54	2005.90	2004.99	1919.18
Tangible Book Value	39,372	40,195	36,664	32,789	32,794	31,421
Tangible Book Value Per Share	2396.46	2446.55	2232.27	1997.55	1999.26	1917.17
Order Backlog	-	56,408	44,720	33,015	26,003	22,425

Source: S&P Global Market Intelligence. Standard template. Financial Sources.